DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer Presented ByDr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan TrialPhase 2, DESTINY-Gastric01 ConferenceASCO GI 2022 21 March, 2022 11:17
ASCO GI 2022 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASCO GI 2022 8 February, 2022 12:37